

Meltem Ocak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2019060/publications.pdf>

Version: 2024-02-01

37
papers

1,355
citations

516710

16
h-index

361022

35
g-index

37
all docs

37
docs citations

37
times ranked

1878
citing authors

#	ARTICLE	IF	CITATIONS
1	Pre-therapeutic dosimetry of normal organs and tissues of ¹⁷⁷ Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1976-1983.	6.4	166
2	⁶⁸ Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1461-1462.	6.4	127
3	Normal distribution pattern and physiological variants of ⁶⁸ Ga-PSMA-11 PET/CT imaging. <i>Nuclear Medicine Communications</i> , 2016, 37, 1169-1179.	1.1	126
4	Evaluation of PSMA PET/CT imaging using a ⁶⁸ Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. <i>Nuclear Medicine Communications</i> , 2015, 36, 582-587.	1.1	125
5	Comparison of ⁶⁸ Ga-DOTATATE and ⁶⁸ Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1271-1277.	6.4	119
6	The accuracy of ⁶⁸ Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1806-1812.	6.4	89
7	Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1426-1435.	6.4	70
8	FDG and FDG-labelled leucocyte PET/CT in the imaging of prosthetic joint infection. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 556-564.	6.4	57
9	^{Lu-177} -PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry. <i>Molecular Imaging and Radionuclide Therapy</i> , 2017, 26, 62-68.	0.7	53
10	¹⁷⁷ Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours. <i>Nuclear Medicine Communications</i> , 2018, 39, 789-796.	1.1	53
11	Cyclic Minigastrin Analogues for Gastrin Receptor Scintigraphy with Technetium-99m: Preclinical Evaluation. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4786-4793.	6.4	43
12	Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system. <i>Nuclear Medicine Communications</i> , 2011, 32, 887-895.	1.1	33
13	The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels. <i>Nuclear Medicine Communications</i> , 2017, 38, 149-155.	1.1	32
14	Folate Receptor-Targeted Multimodality Imaging of Ovarian Cancer in a Novel Syngeneic Mouse Model. <i>Molecular Pharmaceutics</i> , 2015, 12, 542-553.	4.6	27
15	Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer. <i>Nuclear Medicine Communications</i> , 2013, 34, 1084-1089.	1.1	22
16	Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a ¹⁷⁷ Lu-DOTA-minigastrin derivative. <i>Nuclear Medicine and Biology</i> , 2011, 38, 171-179.	0.6	21
17	Preparation and <i>in-vivo</i> evaluation of dimenhydrinate buccal mucoadhesive films with enhanced bioavailability. <i>Drug Development and Industrial Pharmacy</i> , 2016, 42, 916-925.	2.0	18
18	Evaluation of F-18 DOPA PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with Ga-68 DOTA-TATE PET/CT. <i>Annals of Nuclear Medicine</i> , 2021, 35, 900-915.	2.2	18

#	ARTICLE	IF	CITATIONS
19	Performance of F-18 Fluorocholine PET/CT for Detection of Hyperfunctioning Parathyroid Tissue in Patients with Elevated Parathyroid Hormone Levels and Negative or Discrepant Results in conventional Imaging. Korean Journal of Radiology, 2020, 21, 236.	3.4	17
20	Interobserver and intraobserver agreement on prostate-specific membrane antigen PET/CT images according to the miTNM and PSMA-RADS criteria. Nuclear Medicine Communications, 2020, 41, 759-767.	1.1	16
21	Post-therapy imaging of ²²⁵ Ac-DOTATATE treatment in a patient with recurrent neuroendocrine tumor. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2711-2712.	6.4	15
22	Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours. Nuclear Medicine Communications, 2013, 34, 727-732.	1.1	14
23	Preclinical Evaluation of ¹⁸ F-ML-10 to Determine Timing of Apoptotic Response to Chemotherapy in Solid Tumors. Molecular Imaging, 2017, 16, 153601211668594.	1.4	14
24	Impurity in ⁶⁸ Ga-Peptide Preparation Using Processed Generator Eluate. Journal of Nuclear Medicine, 2010, 51, 495.1-495.	5.0	11
25	The role of ⁶⁸ Ga-DOTA-TATE PET/CT scanning in the evaluation of patients with multiple myeloma. Nuclear Medicine Communications, 2017, 38, 76-83.	1.1	11
26	The Diagnostic Efficiency of ^{99m} Tc-EDDA/HYNIC-Octreotate SPECT-CT in Comparison with ¹¹¹ In-Pentetrotide in the Detection of Neuroendocrine Tumours. Molecular Imaging and Radionuclide Therapy, 2013, 22, 76-84.	0.7	11
27	EANM guideline on quality risk management for radiopharmaceuticals. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3353-3364.	6.4	11
28	⁶⁴ Cu-Labeled Phosphonate Cross-Bridged Chelator Conjugates of c(RGDyK) for PET/CT Imaging of Osteolytic Bone Metastases. Cancer Biotherapy and Radiopharmaceuticals, 2018, 33, 74-83.	1.0	9
29	ESTIMATION OF THE ORGAN ABSORBED DOSES AND EFFECTIVE DOSE FROM ⁶⁸ Ga-PSMA-11 PET SCAN. Radiation Protection Dosimetry, 2018, 182, 518-524.	0.8	8
30	Clinical value of technetium-99m-labeled octreotide scintigraphy in local recurrent or metastatic medullary thyroid cancers. Nuclear Medicine Communications, 2013, 34, 1190-1195.	1.1	5
31	The different distribution patterns of FDG and FDG-labelled WBC in inflammatory and infectious lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1660-1661.	6.4	4
32	[⁶⁸ Ga]DOTA-FAPI-04 PET/CT imaging in a case of a signet ring cell carcinoma of stomach. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4523-4524.	6.4	4
33	Intraoperative Localization of Recurrent Medullary Carcinoma of the Thyroid Using Tc-99m HYNIC-TATE and a Surgical Gamma Probe. Clinical Nuclear Medicine, 2011, 36, 831-833.	1.3	2
34	The Role of ⁶⁸ Ga-PSMA PET/CT Scan In Patients with Prostate Adenocarcinoma who Underwent Radical Prostatectomy. Urology Journal, 2020, 18, 58-65.	0.4	2
35	Almost Complete Response with a Single Administration of ²²⁵ Ac-DOTATATE in a Patient with a Metastatic Neuroendocrine Tumor of Unknown Primary. Molecular Imaging and Radionuclide Therapy, 2022, 31, 139-141.	0.7	2
36	Recent Developments of Radiopharmaceuticals for Neuroendocrine Tumor Imaging and Therapy. , 2021, 7, 331-338.		0

#	ARTICLE	IF	CITATIONS
37	Theranostic radiopharmacy for the nuclear medicine and molecular imaging. , 2022, , 235-242.		0